skip nav
  Home | About CDC | Press Room | A-Z Index | Contact Us
spacer
CDC Centers for Disease Control and Prevention Home Page
CDC en Español
Search:  
CDC Home > HIV/AIDS > Topics > Statistics and Surveillance > Reports > Enhanced Perinatal Surveillance United States, 1999–2001
spacer
spacer spacer
spacer
 
Skip Nav spacer
spacer
Table 15. Number and percentage of infants receiving prophylaxis against Pneumocystis carinii pneumonia, by year of birth, 1999–2001—24 areas conducting Enhanced Perinatal Surveillance
spacer
spacer
View PDF PDF icon
  Year of infant's birth   Cumulative
Total
  1999   2000   2001  
Prophylaxis received No. %   No. %   No. %   No. %
Yes 1186 39   1255 40   909 38   3350 39
No 416 14   497 16   395 16   1308 15
Unknown 1409 47   1401 44   1109 46   3919 46
 
Total 3011     3153     2413     8577 100
Note. Because of rounding, column percentages may not total 100. Prophylaxis is recommended for children infected with, or perinatally exposed to, HIV. The recommended medication is trimethoprim/sulfamethoxazole (TMP-SMX); medications such as dapsone or aerosolized pentamidine can be used if TMP-SMX is not well tolerated (CDC, 1995 Revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus, MMWR 1995;44[No. RR-4]:1–11).
Last Modified: September 19, 2006
Last Reviewed: September 19, 2006
Content Source:
Divisions of HIV/AIDS Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
spacer
spacer
spacer
spacer
  Home | Policies and Regulations | Disclaimer | e-Government | FOIA | Contact Us
spacer
spacer
spacer Safer, Healthier People
spacer
Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348, 24 Hours/Every Day - cdcinfo@cdc.gov.		 spacer USA.gov: The U.S. Government's Official Web PortalDHHS Department of Health
and Human Services